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Introduction
Prion diseases, also known as transmissible spongiform enceph-
alopathies, are a group of progressive and fatal neurodegenera-
tive disorders affecting humans (such as Creutzfeldt-Jakob dis-
ease, kuru, Gerstmann-Sträussler-Scheinker disease, and fatal 
familiar insomnia) and several other mammals (such as scrapie 
in sheep and goats, bovine spongiform encephalopathy in cattle, 
and chronic wasting disease in deer, moose, and elk) (1, 2). Prion 
diseases are characterized by the deposition of scrapie prion pro-
tein (PrPSc), a misfolded form of cellular prion protein (PrPC), in 
the CNS. This deposition is accompanied by neuronal loss, spon-
giform change, and gliosis. The etiology of prion diseases can be 
sporadic, heritable, or transmissible between individuals, making 
it unique among neurodegenerative disorders. The transmission 
of prions caused an epidemic of kuru in Papua New Guinea in the 
1950s and 1960s and a bovine spongiform encephalopathy (also 
known as mad cow disease) crisis in the 1980s and 1990s (3, 4). 
Of even greater concern is the observation that bovine spongiform 
encephalopathy has been transmitted to humans by the consump-
tion of prion-contaminated meat, causing hundreds of cases of 
variant Creutzfeldt-Jakob disease (5). According to the protein- 
only hypothesis of prion disease, the infectious agent consists 
of mainly, if not solely, PrPSc (6). PrPSc acts as a propagon to 
recruit and convert PrPC to its own conformation through a self- 
perpetuating reaction. Like most other neurodegenerative disor-
ders, prion diseases are incurable thus far.
Microglia are resident myeloid cells of the CNS that originate 
from c-Kit+ erythromyeloid precursors in the yolk sac and migrate 
to the developing neural tube for maturation, following a stepwise 
developmental program (7–11). Microglia play crucial roles in early 
development of the brain as well as the maintenance of brain 
homeostasis throughout life. Impairment of microglial functions 
can lead to severe pathological outcomes. For instance, disruption 
of the homeobox gene Hoxb8 in microglia results in a phenotype 
of excessive grooming in mice, mimicking trichotillomania in 
humans, an obsessive-compulsive spectrum disorder (12). Defi-
ciency of the fractalkine receptor (CX3CR1), which is exclusively 
expressed by microglia in the CNS, leads to a transient reduction 
of microglia number in the developing brain and delayed synaptic 
pruning and circuit maturation (13). Additionally, microglia have 
been reported to play an important role in learning and memory 
by promoting learning-dependent synapse formation through 
brain-derived neurotrophic factor (BDNF) signaling (14).
As the primary immune cells and phagocytes in the CNS, 
microglia are highly dynamic and continuously patrol the brain 
parenchyma to engulf and clear apoptotic cells and cell debris (15). 
Microglia are also considered the most sensitive sensors of brain 
pathology. Under stimuli such as brain injury, microbial infec-
tion, or neurodegeneration, microglia can be activated, leading to 
morphological and molecular changes and cytokine release (16). 
Depending on the type of stimuli and pathological context, as well 
as the signals from the surrounding microenvironment, microglia 
can take on different activation states and become either neuro-
protective or neurotoxic (17). Activated microglia can exert det-
rimental effects by producing proinflammatory mediators, such 
as TNF-α, IL-1β, IL-6, NO, and ROS (18). Alternatively, activated 
microglia can mediate beneficial effects through the release of 
antiinflammatory factors, such as IL-4, IL-10, and TGF-β (19).
Microglial activation represents one of the hallmarks of many 
neurodegenerative diseases (20). However, prion disease is often 
associated with dramatic and conspicuous microglial activation 
(16). Study of prion diseases has benefited from mouse models of 
prion infection. Upon infection, WT mice can recapitulate most 
pathological features of prion diseases, including microglial acti-
vation. In this Review, we discuss microglial activation and cyto-
kine release during prion disease progression and the overall role 
of microglia in prion pathogenesis, highlight the molecular mech-
anisms underlying the microglial response to prion infection, and 
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prion-induced neurodegeneration. Interestingly, 
microglial activation may vary between differ-
ent human prion disease subtypes, since West-
ern blots and immunohistochemical assays have 
demonstrated unaltered microglia in fatal familiar 
insomnia and genetic Creutzfeldt-Jakob disease 
(G114V) patients (30).
Along with microglial activation, expres-
sion of proinflammatory cytokines such 
as TNF-α, IL-1α, and IL-1β is significantly 
increased in brains of prion-infected mice and 
Creutzfeldt-Jakob disease patients (31–33). 
Time course studies in mouse models of prion 
infection found that the temporal pattern of 
cytokine upregulation correlated with the onset 
and development of molecular and clinical 
prion pathology (31). The induction of cyto-
kines in prion-infected mice was predominantly 
observed in brain regions showing neurodegen-
eration and spongiform change (34), suggesting 
that cytokines may play an important role in 
prion pathogenesis. Intriguingly, the induc-
tion of cytokine expression in mouse models of 
prion infection depends on prion strain/mouse 
genetic background combinations, since ME7- 
infected C57BL/6J mice failed to show any sig-
nificant change in cytokine profiling (35).
Microglia activation–associated cytokine 
release may not always be proinflammatory. 
In different rodent models of prion diseases, the antiinflamma-
tory cytokine TGF-β was also progressively upregulated (36, 37); 
however, the temporal patterns and extent of upregulation varied 
substantially among models, implying that the induction of cyto-
kine differs according to prion strain and species infected (36). 
Similarly, levels of the antiinflammatory cytokines IL-4 and IL-10 
were also increased in the cerebrospinal fluid of Creutzfeldt-Jakob 
disease patients (38).
A comprehensive study of microglial response in prion disease 
was performed by whole transcriptome profiling of prion-infected 
mouse brains. This study revealed that the genes upregulated after 
prion infection, regardless of the prion strain or mouse genetic 
background, are expressed predominantly by activated microglia 
(39), contributing to a growing recognition of the importance of 
microglia in prion pathogenesis. Analysis of microglia isolated from 
prion-infected mice demonstrated that, in addition to an upregu-
lation of genes associated with metabolic and respiratory stress, 
a disease-specific, highly proinﬂammatory profile was observed 
(39). Another transcriptomic analysis of various brain regions in the 
presence or absence of neurodegeneration revealed that there are 
at least two distinct microglial responses in prion-infected brains: 
a homeostatic response across all brain regions and an innate 
immune response restricted to sites of neurodegeneration (40).
In conclusion, microglial activation during prion disease 
progression is a complex and multistep process, with activated 
microglia comprising a heterogeneous population with diverse 
functions. At early stages of prion infection, microglia respond to 
PrPSc deposits and consequently increase their phagocytic capacity 
review the role of microglia-related molecules in prion pathogene-
sis. In view of recent advances in understanding the role of microg-
lia in prion diseases, we discuss potential therapeutic targets for 
prion diseases based on modulation of microglial activation.
Microglial activation and cytokine release in 
prion diseases
Prion infection typically does not trigger an overt adaptive 
immune response in the periphery. Classical leukocyte infiltration 
and inflammatory response are usually absent in prion-infected 
brains (21). Neuronal loss and astrogliosis have been well docu-
mented during early studies of prion neuropathology; however, 
microglial activation has received less attention. By immunohis-
tochemical analysis, microglia were first observed to be closely 
associated with plaques in Creutzfeldt-Jakob disease, Gerstmann- 
Sträussler-Scheinker, and kuru (22–24). Compared with nonprion 
controls, immunohistochemical staining with microglial mark-
ers revealed markedly increased microglia in Creutzfeldt-Jakob 
disease and animal models of prion diseases (25, 26). The mor-
phology of the microglia changed to an activated state, providing 
evidence of a microglial response in prion diseases.
Time course studies revealed that microglial activation appeared 
at an early phase of prion disease, before neuronal loss, spongiform 
change, and the onset of clinical signs (27–29), indicating that microg-
lial activation might contribute to neurodegeneration as opposed to 
occurring merely as a secondary effect. Moreover, the distribution of 
microglial response correlates with spongiform change and astrogli-
osis, implying a close association between microglial activation and 
Figure 1. Microglial activation in prion disease. At an early stage of prion infection and PrPSc 
aggregation, microglia are activated by PrPSc. Microglia then acquire a phagocytic phenotype and 
produce several antiinflammatory cytokines such as IL-4, IL-10, and TGF-β. The phagocytosis of 
prions by microglia is facilitated by the astrocyte-derived opsonin MFGE8. However, over time, 
the clearance of prion becomes insufficient, and sustained PrPSc accumulation leads to neuronal 
damage. This damage may trigger microglia to switch to a proinflammatory phenotype with 
secretion of TNF-α, IL-1β, and IL-6. Such inflammatory cytokines may also convert astrocytes to 
a deleterious A1 phenotype.
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that the neuronal damage was attenuated and prion progression 
was delayed upon treatment with CSF1 receptor (CSF1R) inhibitor 
to arrest microglial proliferation, suggesting a detrimental role of 
microglial proliferation in prion diseases (44).
In an ex vivo model of prion diseases, ganciclovir-mediated 
microglial depletion in cerebellar organotypic cultured slices 
from tga20/CD11b–thymidine kinase of herpes simplex virus 
(tga20/CD11b–HSVTK) transgenic mice resulted in enhanced 
PrPSc deposition and increased prion titer. These results suggest 
that microglia play an important role in clearing prions (45, 46). 
The same ex vivo model was used to determine the effect of 
microglial depletion on prion-induced neurodegeneration. After 
microglial depletion, not only PrPSc accumulation but also neu-
rotoxicity of prions were drastically enhanced, and prion pathol-
ogy was markedly aggravated (47). Moreover, while the tga20/
CD11b–HSVTK transgenic mice were intracerebrally infected 
with prions, followed by implantation of osmotic minipumps con-
taining ganciclovir to deliver the drug directly into the brain, the 
incubation time of prion-infected microglia-depleted mice was 
significantly shortened (47). Additionally, when prions were inoc-
ulated into Il34–/– mice, which contain fewer microglia because 
of impaired microglial development and maintenance (48, 49), 
PrPSc deposition was augmented and prion progression was accel-
erated in comparison with infected WT littermates (47). There-
fore, we contend that microglia play a generally neuroprotective 
rather than deleterious role in prion pathogenesis (Figure 2). Neu-
roprotection by microglia is mediated, at least partly, by prion 
to remove PrPSc. However, this phagocytosis is insufficient, and 
sustained PrPSc accumulation leads to neuronal damage, which 
could in turn trigger the microglia to switch to a proinflammatory 
phenotype and exert detrimental effects in the brain (Figure 1).
Overall role of microglia in prion pathogenesis
Although microglial activation is now well established and is con-
sidered a hallmark of prion neuropathology, the overall role of 
microglia in prion pathogenesis has remained contentious. Microg-
lia are a highly dynamic and motile cell population in the CNS. In 
prion-infected mice, microglia are observed surrounding PrPSc 
deposits and intracellular PrPSc can be detected within microg-
lia (22–24, 41, 42). The presence of prion infectivity in microglia 
suggests that microglia might help disseminate prion within the 
brain. Activated microglia in prion-infected brain produce proin-
flammatory cytokines that may conceivably contribute to disease 
progression. However, microglia are professional phagocytes that 
can engulf and degrade prions, thereby decreasing prion load and 
slowing down prion progression.
A study using the prion protein–derived peptide PrP106–126 to treat 
primary cell cultures demonstrated that microglia are required for 
PrP106–126-induced cytotoxicity in primary neurons, suggesting that in 
this context microglia are an important mediator of neuronal death 
(43). However, PrP106–126 treatment is fundamentally different from 
prion infection, since the PrP106–126 peptide has never been detected 
in vivo and is not infectious per se. This raises serious doubts about 
the relevance and validity of the findings. Another study reported 
Figure 2. Microglia play a neuroprotective role 
in prion pathogenesis. Cerebellar organotypic 
cultured slices prepared from tga20/CD11b–HSVTK 
transgenic mice were infected with prions, fol-
lowed by ganciclovir treatment. This leads to an 
efficient depletion of microglia and, consequently, 
enhanced PrPSc deposition and neurotoxicity. 
Tga20/CD11b–HSVTK transgenic mice were first 
intracerebrally inoculated with prions. Ganciclovir 
was then delivered to the brain through osmotic 
pumps. As a result, prion pathogenesis was greatly 
enhanced. Similarly, when Il34–/– mice (which 
contain fewer microglia than WT mice) were intra-
cerebrally inoculated with prions, PrPSc accumula-
tion was augmented and disease progression was 
accelerated. These results provide evidence for an 
overall neuroprotective role of microglia in prion 
pathogenesis.
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in the morphology and function of peripheral lymphoid structures 
(52). Mice that lack the adaptor protein MyD88 (Myd88−/− mice), 
which are defective in most TLR signaling and IL-1 receptor (IL-1R) 
signaling, were challenged intraperitoneally or intracerebrally with 
the standard Rocky Mountain Laboratory (RML) strain of prions. 
Myd88−/− mice succumbed to prion disease after incubation times 
similar to those of WT mice (Table 1), suggesting that Myd88- 
dependent TLR signaling or IL-1R signaling does not play a major 
role in prion pathogenesis (53). Nevertheless, another study 
observed a significantly shortened incubation time in C3H/HeJ 
(Tlr4Lps-d) mice, which possess a mutation in the TLR4 intra-
cellular domain that prevents TLR4 signaling, compared with the 
strain-matched WT control (C3H/HeOuJ). Therefore, stimulation 
of TLR4, perhaps via a Myd88-independent pathway, may play a 
protective role in prion pathogenesis (54). In accordance with this 
observation, mice deficient in IFN regulatory factor 3 (Irf3–/–), a key 
transcription factor of the MyD88-independent type I IFN produc-
tion pathway, showed a significantly earlier onset of prion pathol-
ogy than WT controls. In addition, overexpression of IRF3 in a cell 
culture system attenuated prion infection, whereas prion-infected 
cells treated with IRF3-targeted siRNAs accumulated more PrPSc 
clearance. These results also suggest that prion dissemination in 
the CNS is not executed by microglia. In line with this conclusion, 
when prion-infected mice were subjected to an additional intra-
peritoneal infection of Moloney murine leukemia virus, which can 
invade the brain, an enhanced microglial activation associated 
with transient clearance and delayed accumulation of prions in 
the brain were observed (50).
Microglia-related transducers in prion diseases
Toll-like receptors. As discussed above, prion progression is accom-
panied by conspicuous microglial activation; however, the molecu-
lar mechanisms underlying the microglial response to prion infec-
tion are not well defined. Toll-like receptors (TLRs) are a class of 
pattern-recognition receptors that recognize invading pathogens to 
initiate the innate immune response. Therefore, TLRs are poten-
tial candidates involved in prion-induced microglial activation to 
defend against prion infection.
An early study reported that repeated stimulation of TLR9 
by unmethylated CpG oligodinucleotides was protective in mice 
peripherally inoculated with prions, resulting in delay or prevention 
of disease (51). This protection was revealed to be due to alterations 
Table 1. Role of microglia-related molecules in prion pathogenesis in the CNS
Mouse line Genetic 
background
Prion strain Effects (in comparison with WT mice on the same genetic background) References
Myd88–/– C57BL/6 RML None 53
C3H/HeJ (Tlr4Lps-d) C3H 139A or ME7 Shortened incubation time by 14.5–28 days 54
Irf3–/– C57BL/6 22L, Fukuoka-1, or mBSE Shortened incubation time by 24–70 days 55
Cd14–/– C57BL/6 Chandler or Obihiro Enhanced microglial activation, delayed PrPSc accumulation, increased antiinflammatory cytokines and 
decreased proinflammatory cytokines, decelerated progression of disease by 8–14 days
56, 57
Il1r1–/– C57BL/6 139A Delayed astrocytosis, enhanced microglial activation, and prolonged incubation time by 5–22 days 64
B6;129S1/Sv RML Prolonged incubation time by 21 days 65
Il4–/– BALB/c RML Accelerated disease progression by 29 days at low-dose inoculum 67
Il13–/– BALB/c RML Accelerated disease progression by 39 days at low-dose inoculum 67
Il10–/– 129Sv RML or ME7 Enhanced inflammation and shortened incubation time by 41–82 days 67
129S6 RML None 65
C57BL/6J RML Shortened incubation time by 34 days 65
Ccl2–/– C57BL/6J ME7 Unaltered early behavioral dysfunction, but delayed incubation time by 2–3 weeks 68
C57BL/6J RML None 69
Ccr1–/– C57BL/6 RML Enhanced ERK1/2 activation, shortened incubation time by 15 days 70
Cxcr3–/– C57BL/6 139A Accelerated PrPSc accumulation, reduced microglial activation and production of proinflammatory 
cytokines, delayed incubation time by 20–30 days
72
Cx3cr1–/– BALB/c Chandler/RML, ME7, or MRC2 No changes in microglial activation or cytokine profiling, but shortened incubation time by 6–10 days 82
C57BL/6 RML None 83
Galectin-3–/– C57BL/6 139A Decreased lysosomal activation, prolonged incubation time by 16–22 days 84
Nlrp3–/– C57BL/6 RML None 89
Pycard–/– C57BL/6 RML None 89
Nox2–/– C57BL/6 22L Abrogated ROS production, ameliorated clinic symptoms, and prolonged survival times by 6.5–8 days 
for males with both high- and low-dose inoculum and 15.5 days for females with low-dose inoculum; no 
effect was observed in females with high-dose inoculum
90
Mfge8–/– C57BL/6 × 
129Sv
RML Augmented PrPSc accumulation, accelerated prion progression by 23–43 days 94
Trem2–/– C57BL/6 RML Attenuated microglial activation, unaltered prion progression 103
Il34–/– C57BL/6 RML Enhanced PrPSc deposition, accelerated prion progression by 14–21 days 47
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study showed a correlation between SNPs in the Il1r1 locus and 
incubation time in mouse models of prion diseases, supporting 
the involvement of IL-1R1 signaling in prion pathogenesis (66).
Several antiinflammatory cytokines have been examined for 
their contribution to prion disease. While deficiency in IL-4 or IL-13 
had minor or negligible effects on prion disease progression, defi-
ciency in IL-10 on a 129Sv background markedly shortened time 
between inoculation and onset of clinical symptoms (67). In the 
absence of IL-10, expression of the proinflammatory cytokine TNF-α 
was enhanced at an early disease stage, which could account for the 
enhanced prion pathology in Il10–/– mice. This study suggests that the 
antiinflammatory cytokine IL-10 has a neuroprotective role in prion 
pathogenesis. Interestingly, the neuroprotective role of IL-10 in prion 
disease seems to depend on the genetic context, since another study 
observed only a mild acceleration of prion progression in Il10–/– mice 
on a C57BL/6 background but not on a 129S1/SvImj background (65).
Chemokines. Most neurodegenerative disorders, including prion 
diseases, are associated with upregulation of chemokine expression. 
For instance, expression of the chemokine ligand CCL2 (also known 
as monocyte chemoattractant protein-1, MCP-1), is coordinately 
upregulated in the CNS with disease progression in C57BL/6 mice 
infected with ME7 prions (68). The increased expression of CCL2 
also positively correlated with microglial activation. Following inoc-
ulation of ME7 prions, Ccl2–/– mice experienced microglial activation 
or neuronal death in the hippocampus and thalamus at levels similar 
to those of WT controls, but disease incubation time was significantly 
prolonged by CCL2 deficiency (68). Interestingly, the effect of CCL2 
on prion pathogenesis might be prion strain–dependent, since Ccl2–/– 
mice failed to show any changes in disease progression after inocula-
tion of RML prions (69). Mice lacking the CCL2 receptor CCR2 dis-
played similar disease progression to WT mice following RML prion 
challenge (21, 65). However, CCR2 deficiency blocked recruitment of 
perivascular macrophages in the diseased CNS and resulted in a mild 
reduction in microglia proliferation (21).
Expression of CCL5 (also known as RANTES) and its receptors 
CCR1, CCR3, and CCR5 is also increased in mouse models of prion 
diseases (36). CCR1 deficiency resulted in augmented induction of 
CCR5 and CCR3, probably by a compensatory mechanism, leading 
to enhanced activation of ERK1/2 and accelerated disease progres-
sion in prion-infected mice (70). However, mice lacking CCR5 devel-
oped prion disease at a rate similar to that of WT controls following 
RML prion inoculation (65). Thus, the exact role of these chemokine 
and chemokine receptors in prion pathogenesis remains unclear.
CXCL9 and CXCL10, which recognize and bind to CXCR3, 
are also increased in prion infection (64, 71). After intracerebral 
inoculation of 139A prion, Cxcr3–/– mice accumulated more PrPSc 
in their brains compared with WT mice, but succumbed to dis-
ease with a prolonged incubation time (72). Further character-
ization of these mice revealed that absence of CXCR3 reduced 
microglial activation and consequently impaired prion phagocy-
tosis and degradation, leading to enhanced PrPSc accumulation. 
However, depletion of CXCR3 resulted in reduced production of 
proinflammatory cytokines, which could explain the prolonged 
incubation time. The chemokine CXCL13 is also upregulated in 
prion disease (42, 71); however, knockout of its receptor, CXCR5, 
did not alter prion pathogenesis after intracerebral inoculation 
of RML prions (73).
(55). These results indicate that IRF3 negatively regulates PrPSc 
formation and prion pathogenesis, providing new insight into the 
role of the innate immune system in the response to prion infec-
tion. Overall, these results suggest a general protective role of cer-
tain TLR signaling pathways in prion pathogenesis. Since TLRs 
are expressed by various cell types in the CNS, microglia-specific 
manipulation of TLRs (such as by Cx3cr1-Cre–dependent condi-
tional knockout of TLRs) is required to further determine the role 
of microglial TLRs in prion pathogenesis.
CD14 is a glycosylphosphatidylinositol-anchored (GPI-anchored) 
protein mainly expressed by microglia in the CNS. CD14 acts as a 
TLR4 coreceptor to recognize LPS. Upregulation of CD14 expres-
sion associated with aggregated proteins has been observed in 
both patients and mouse models of neurodegenerative disorders 
including prion diseases. Upon intracerebral challenge with prions, 
Cd14–/– mice survived longer than WT mice, suggesting that CD14 
contributes to prion disease progression. Quantification of PrPSc 
revealed that accumulation of PrPSc was delayed in Cd14–/– mice 
compared with WT controls. This is associated with enhanced 
microglial activation in prion-infected Cd14–/– mice. Moreover, the 
microglia-derived antiinflammatory cytokines IL-10 and TGF-β 
and neuron-derived IL-13 appeared to be expressed earlier in 
prion-infected Cd14–/– mice. In contrast, expression of the proin-
flammatory cytokine IL-1β in microglia appeared to be decreased 
in Cd14–/– mice in the early stage of prion infection. These results 
imply that CD14 plays a detrimental role in prion pathogenesis by 
promoting proinflammatory responses and/or inhibiting antiin-
flammatory responses in the brain (56, 57).
Complement systems. As an integral part of the innate 
immune system, the complement system provides an important 
immune-mediated defense against pathogens. We have long held 
the view that complement facilitates prion pathogenesis by trapping 
and retaining prions in secondary lymphoid organs after peripheral 
infection (58, 59). The complement cascade was reported to be 
activated in the brains of patients with Creutzfeldt-Jakob disease 
and Gerstmann-Sträussler-Scheinker disease, as well as in animal 
models of prion infection (60–62). Overall, complement activity 
was upregulated in several prion-infected rodent brains in a time- 
dependent manner, and complement components such as C1q, C3, 
and membrane attack complex (MAC) were also upregulated and 
detected in various cell types, including microglia (62). Neverthe-
less, the contribution of the complement system in prion-induced 
neurodegeneration in the CNS seems to be minor, as mice deficient 
in various complement components developed disease similarly to 
WT mice upon intracerebral challenge with prions (58, 59, 63).
Cytokines. As discussed above, microglial activation in prion 
disease is typically associated with increased production of cyto-
kines. The involvement of cytokines in prion pathogenesis was 
elucidated by challenging of different mouse models lacking or 
overexpressing specific cytokines with prions. While most cyto-
kines (TNF-α, IL-6, TGF-β1, etc.) do not play an important role in 
prion-induced neurodegeneration in the CNS, knockout of IL-1 
receptor 1 (IL-1R1), which is the receptor for IL-1α and IL-1β, led 
to a modest but statistically significant delay in disease progres-
sion (64, 65). This may be due to delayed astrogliosis and/or aug-
mented microglial activation that contribute to enhanced phago-
cytosis of prions in Il1r1–/– mice. Additionally, an association 
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CX3CR1, the receptor of the neuron-expressed chemokine 
CX3CL1 (also known as fractalkine), is exclusively expressed by 
microglia in the CNS (74, 75). CX3CL1/CX3CR1 signaling rep-
resents one example of the neuron-microglia crosstalk that main-
tains microglia in a quiescent state (76). CX3CR1 has been exten-
sively studied in several models of neurodegeneration, such as 
Alzheimer’s disease (AD), Parkinson’s disease, and amyotrophic 
lateral sclerosis; however, conflicting results have been reported 
in these models (77–80). In animal models of prion infection, the 
CX3CL1/CX3CR1 axis has been reported to be altered (75, 81). 
The role of CX3CR1 in prion disease has been studied by two 
independent groups. While one group demonstrated that lack of 
CX3CR1 led to modest but significant reductions in incubation 
time (82), suggesting a neuroprotective role of CX3CR1 signaling 
in prion pathogenesis, the other group failed to find any differ-
ence in disease onset, duration of disease, or pathology of dis-
ease between the Cx3cr1–/– mice and WT controls (83). The dis-
crepancy between these two studies may be due to the distinct 
mouse strains or different experimental protocols used in each 
study. Nevertheless, neither study observed any obvious effect 
of CX3CR1 on prion-induced microglial activation. Moreover, 
these studies suggest an overall minor effect of CX3CR1 on pri-
on pathogenesis. Therefore, as in other neurodegeneration mod-
els, the role of CX3CR1 in prion disease may vary with different 
experimental systems.
Inflammation regulators. Galectin-3 is a multifunctional pro-
tein and, in particular, a regulator of inflammation. Immunoflu-
orescence staining identified microglia as the major source of 
galectin-3 in the brain. Expression of galectin-3 is significantly 
upregulated in prion-infected brains. Upon prion infection, 
galectin-3 deficiency did not affect PrPSc deposition or the devel-
opment of gliosis. However, galectin-3–/– mice showed prolonged 
survival times after prion infection. Interestingly, expression 
of the lysosomal activation marker LAMP-2 was profoundly 
decreased in prion-infected galectin-3–/– mice, suggesting that 
galectin-3 is involved in regulation of lysosomal function. These 
results suggest a detrimental role of galectin-3 in prion patho-
genesis in the CNS and indicate that lysosomal dysfunction may 
contribute to prion disease progression (84).
The inflammasome is a cytosolic multiprotein complex that 
serves as a scaffold for activating the proinflammatory cyto-
kines IL-1β and IL-18 via caspase-1–mediated cleavage. The 
NLRP3 inflammasome has been reported to be activated in AD 
and contributes to pathology in a mouse model of AD (85, 86). 
In in vitro cell culture models using microglia cell lines or pri-
mary murine microglia, the NLRP3 inflammasome was found 
to be essential for IL-1β release upon treatment with PrP106–126 
peptide (87) or PrP fibrils (88). However, whether the NLRP3 
inflammasome can recognize bona fide prions and affect prion 
pathogenesis in vivo was unknown. The role of the NLRP3 
inflammasome in mouse models of prion disease was assessed 
by intracerebral inoculation of RML prions into mice deficient 
in NLRP3 (Nlrp3–/–) or the inflammasome adaptor protein ASC 
(Pycard–/–). Both Nlrp3–/– and Pycard–/– mice developed the clas-
sic symptoms of prion diseases and succumbed to scrapie with 
attack rates and survival times similar to those of WT controls. 
Additionally, the absence of NLRP3 or ASC did not significantly 
change levels of IL-1β in the brain at the terminal stage of the 
disease. Thus, based on existing data, NLRP3 and ASC do not 
play significant roles in prion pathogenesis (89).
Reactive oxygen species and NOX2. Prion-induced neurode-
generation is often accompanied by the production of reactive 
oxygen species (ROS) and oxidative stress. Indeed, NOX2, 
a membrane-bound electrochemical pump and a prominent 
NADPH oxidase that generates ROS, is markedly upregulated 
in microglia within affected brain regions of patients with 
Creutzfeldt-Jakob disease, as well as in prion-inoculated mouse 
brains and cerebellar organotypic cultured slices. Upon chal-
lenge with prions, NOX2-deficient mice showed delayed onset 
of motor deficits and a significant prolongation of incubation 
time compared with WT mice. Dihydroethidium assays demon-
strated a marked ROS burst at the terminal stage of disease in 
WT mice, but not in NOX2-deficient mice. Thus, NOX2 is a 
major contributor to excessive production of ROS in prion dis-
eases and therefore affects prion pathogenesis (90).
Phagocytosis mediators. Milk fat globule epidermal growth factor 
8 (MFGE8) is a bifunctional secreted molecule that can bind to both 
phosphatidylserine on apoptotic cells and integrins on phagocytes, 
thereby bridging apoptotic bodies and phagocytes and facilitating 
phagocytosis (91). Because prion infectivity is usually associated 
with lipids (92, 93), it is conceivable that MFGE8 is involved in prion 
clearance by microglia in prion-infected brains. Indeed, mice lack-
ing MFGE8 (Mfge8–/–) experienced augmented prion accumulation 
and accelerated disease progression after prion inoculation. Inter-
estingly, the involvement of MFGE8 in microglia-mediated prion 
clearance is mouse strain–dependent, since the effect of MFGE8 
depletion was observed in mice with C57BL/6 ′ 129Sv background 
but not C57BL/6 background (94). This finding also implies the 
existence of further polymorphic determinants of prion clearance.
Triggering receptor expressed on myeloid cells 2 (TREM2) 
is an innate immune cell surface receptor mainly expressed by 
microglia in the brain. TREM2 facilitates phagocytosis of apop-
totic neurons and bacteria, thereby suppressing inflammation 
(95, 96). Dysfunctional variants of TREM2 have been iden-
tified as major genetic risk factors for AD and other neurode-
generative conditions (97–101). Ablation of Trem2 in a mouse 
model of AD (5xFAD) resulted in increased hippocampal Aβ 
burden and accelerated loss of cortical neurons. Interestingly, 
microglial activation was markedly attenuated in 5xFAD mice 
on a Trem2–/– background (102). To explore whether TREM2 is 
also involved in prion clearance by microglia, Trem2–/– mice and 
their WT littermates were intracerebrally inoculated with pri-
ons. Neither PrPSc deposition nor disease progression was dif-
ferent between Trem2–/– and WT mice, suggesting that TREM2 
is not a major player in prion clearance. Nevertheless, similarly 
to what was observed in 5xFAD model, markers of microglial 
activation (IBA1) were significantly reduced in prion-infected 
Trem2–/– mice, suggesting that TREM2 is involved in prion- 
induced microglial activation (103).
Therapeutics of prion disease by  
targeting of microglia
Microglia play an overall neuroprotective role in prion diseases 
and are therefore considered as friend rather than foe. Thera-
Downloaded from http://www.jci.org on August 9, 2017.   https://doi.org/10.1172/JCI90605
The Journal of Clinical Investigation   R E V I E W  S E R I E S :  G L I A  A N D  N E U R O D E G E N E R A T I O N 
7jci.org
peutic strategies against prion disease should be designed to 
avoid depleting or reducing microglia. However, microglia that 
are activated upon prion infection are heterogeneous and can 
adopt different phenotypes. Whereas some activated microg-
lia possess enhanced phagocytosis activity and produce anti-
inflammatory factors, thereby exerting neuroprotective func-
tions, others could be more proinflammatory and neurotoxic in 
the brain. Accordingly, it is conceivable that microglia could be 
guided toward a beneficial state that could efficiently phagocy-
tose prions and secrete antiinflammatory factors to slow down 
disease progression.
Several microglia-related molecules and pathways are 
involved in prion-induced microglial activation and prion 
pathogenesis. Attempts to modulate prion progression by 
blocking TLRs via administration of unmethylated CpG 
oligodinucleotides caused a delay in prion progression in mice 
peripherally inoculated with prions (51). However, this effect 
may have been unrelated to microglia and instead mainly due 
to changes in the morphology and function of peripheral lym-
phoid elements (52). CD14 deficiency confers neuroprotection 
from prion disease by modifying cytokine secretion. Treatment 
with the GPI-specific phospholipase glimepiride could induce 
shedding of CD14 from the cell surface, thereby modifying 
prion progression (104).
CSF1R signaling is one of the mediators of prion-induced 
microglial activation and proliferation. Treatment with the 
selective CSF1R tyrosine kinase inhibitor GW2580 significantly 
reduced microglial proliferation in ME7-infected mice. In addi-
tion, there was decreased expression of proinflammatory cyto-
kines (IL-6 and IL-1β) and increased expression of antiinflamma-
tory cytokines (ARG1 and YM1). Blocking of CSF1R by GW2580 
also improved behavioral performance and prolonged survival of 
prion-infected mice (44). Therefore, manipulation of microglial 
activation to a beneficial phenotype represents a potential thera-
peutic approach for prion disease.
Microglia exert neuroprotection in prion disease, at least 
partly by engulfing and degrading prions; however, phagocy-
tosis and the clearance of prions are inefficient, and animals 
eventually die of the disease (105). This is probably because 
the early phagocytic and antiinflammatory microglia phenotyp-
ically switch to a proinflammatory and less phagocytic pheno-
type at the late stage of disease. Strategies aiming to enhance 
phagocytic capacity of microglia have been explored. Retrovirus 
treatment of prion-infected mice transiently stimulated microg-
lial activation and prion clearance, although the incubation 
time was not altered (50). These results suggest that appropri-
ate stimulation of microglial activation could be beneficial in 
prion disease. However, stimulation of microglia should be 
carefully controlled, since intracerebral or systemic administra-
tion of LPS to ME7-infected mice markedly stimulated microg-
lial activation, but exacerbated the local inflammatory response 
and increased neuronal death (106). Intracerebral injection of 
brain-engraftable murine microglial cells that express an anti-
PrP single-chain variable fragment before or at an early stage 
after prion infection modestly but significantly prolonged the 
incubation times, suggesting a novel microglia-mediated immu-
notherapeutic approach against prion diseases (107).
Perspectives
Microglial activation is now widely recognized in most neuro-
degenerative disorders, including prion diseases. Several mod-
els of microglial depletion and deficiency provide convergent 
evidence of a neuroprotective role of microglia in prion patho-
genesis. However, the exact molecular mechanisms underlying 
the microglial response to prion infection remain to be fully 
elucidated. Moreover, therapeutic strategies that modulate 
the effects of microglia in prion pathogenesis are challenging 
because of the heterogeneity of activated microglia. Character-
ization of the different microglial populations represents a cru-
cial step toward a deeper understanding of microglial activation 
in prion pathogenesis.
Under physiological conditions, CNS microglia undergo 
complex and sometimes subtle interactions with other cell 
types such as neurons or astrocytes to elicit various functions. 
Upon prion infection, microglial activation is usually associated 
with astrogliosis. Previous findings indicate that the astrocyte- 
derived phagocytosis mediator MFGE8 enhances phagocytosis 
of prions by microglia, thus providing an important cross-talk 
between different cell types during prion infection (94). How-
ever, the mechanisms by which microglial activation and astro-
cytes orchestrate their response to prions remain unclear. Clas-
sically activated microglia have been found to induce a putative 
subtype of reactive astrocytes, termed A1, by secreting IL-1α, 
TNF-α, and C1q, leading to a loss of neurotrophic functions and 
neuronal death (108). Thus, microglial activation and astroglio-
sis may be more closely related than has previously been appre-
ciated. Because of the heterogeneity and diversity of astrocyte 
subtypes in the CNS (109), the complex interaction of microglia 
and astrocytes requires further investigation.
A deeper understanding of the role of microglia in prion 
pathogenesis may facilitate the development of techniques to 
manipulate microglial activation and dampen disease progres-
sion. Hopefully, microglial activation can be used as a novel tar-
get to interfere with prion progression. Since neuroinflammation 
including microglial activation is a common feature of many 
neurodegenerative diseases, the study of microglia in prion dis-
eases could reveal important insights into the role of neuroin-
flammation in other neurodegenerative conditions.
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